Allergan eyelash drug wins US panel backing
ROCKVILLE, Md. (Reuters) - An Allergan Inc (AGN.N) glaucoma drug is safe and effective enough for U.S. regulators to approve cosmetic use to lengthen and thicken eyelashes, a U.S. advisory panel unanimously ruled on Friday.
The drug is known generically as bimatoprost and is sold for glaucoma under the name Lumigan. Allergan estimates the eyelash use could fetch more than $500 million in global sales per year.
(Reporting by Susan Heavey; editing by Gerald E. McCormick)